Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Impact · against what's priced in

The announcement of a technical data presentation at ASRS 2026 is a low-impact event, as it focuses on refining patient selection for a trial already underway. The primary valuation driver remains the Phase 3 ARCHER II topline data expected in Q4 2026.

ANNX+0.10

No priced-in read yet